| scholarly article | Q13442814 |
| P50 | author | Flora Musuamba Tshinanu | Q80171194 |
| Donato Teutonico | Q83449830 | ||
| P2093 | author name string | S Yang | |
| M Danhof | |||
| O Della Pasqua | |||
| H J Maas | |||
| A Facius | |||
| P2860 | cites work | The bootstrap: a tutorial | Q30058192 |
| The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data | Q30991419 | ||
| Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation. | Q51088081 | ||
| Bootstrap Methods: Another Look at the Jackknife | Q55950786 | ||
| Simulation of correlated continuous and categorical variables using a single multivariate distribution | Q79280783 | ||
| Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis | Q81386014 | ||
| Targeting population entering phase III trials: a new stratified adaptive phase II design | Q83698290 | ||
| Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma | Q31119684 | ||
| Clinical trial simulation in drug development | Q33912650 | ||
| Simulation of clinical trials | Q33932132 | ||
| Role of modelling and simulation in Phase I drug development | Q34215804 | ||
| Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop | Q34386133 | ||
| Markers of exacerbation severity in chronic obstructive pulmonary disease | Q34691221 | ||
| Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD) | Q34990277 | ||
| Population pharmacokinetics of darbepoetin alfa in healthy subjects | Q36024876 | ||
| Clinical trial simulation: a tool for understanding study failures and preventing them | Q36055589 | ||
| Markers of disease severity in chronic obstructive pulmonary disease. | Q36194379 | ||
| Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis | Q36364005 | ||
| Guidelines for selecting among different types of bootstraps | Q36473350 | ||
| The design of simulation studies in medical statistics | Q36583544 | ||
| Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling | Q36702459 | ||
| Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging | Q37178373 | ||
| Quantitative disease, drug, and trial models | Q37292641 | ||
| Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions | Q37353460 | ||
| A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn | Q37404434 | ||
| An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future | Q37799461 | ||
| Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors | Q39605793 | ||
| What predicts change in pulmonary function and quality of life in asthma or COPD? | Q39767131 | ||
| Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris | Q40611626 | ||
| A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children | Q41597271 | ||
| Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. | Q42638467 | ||
| Enriched analgesic efficacy studies: an assessment by clinical trial simulation | Q42674379 | ||
| Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research | Q42905874 | ||
| Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis | Q43816378 | ||
| Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. | Q46522265 | ||
| Analysis of dose-response in flexible dose titration clinical studies | Q48032502 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P921 | main subject | multivariate statistics | Q1952580 |
| P304 | page(s) | 3228-3237 | |
| P577 | publication date | 2015-05-21 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques | |
| P478 | volume | 32 |
| Q38674852 | Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy |
| Q38675644 | Optimizing drug development in oncology by clinical trial simulation: Why and how? |
| Q91182307 | Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort |
| Q47634067 | The Hepato-Hypothalamic-Pituitary-Adrenal-Renal Axis: Mathematical Modeling of Cortisol's Production, Metabolism, and Seasonal Variation |
Search more.